CD133-negative Glioma Cells Form Tumours, While the Onset of CD133 Expression Coincides with Angiogenesis and Shortened Survival

Jian Wang,Per Øystein Sakariassen,Oleg Tsinkalovsky,Heike Immervoll,Stig Ove Bøe,Lars Prestegarden,Gro Vatne Røsland,Anders Molven,Rolf Bjerkvig,Per Øyvind Enger

IF: 11.2

2007-01-01

Cancer Research

Abstract:AACR Annual Meeting-- Apr 14-18, 2007; Los Angeles, CA LB-91 ABSTRACT Recent work has identified CD133 as a marker of brain tumor-initiating cells. In this study, human glioblastoma biopsies were xenografted intracerebrally into nude rat brains. The resulting tumors expressed little or no CD133, and showed no contrast enhancement suggesting a normal vasculature with an intact blood-brain barrier. During serial passaging in vivo , the tumors gradually displayed more contrast enhancement. Real-time qPCR and immunoblots showed that this change was accompanied by increased angiogenesis, increased CD133 expression and a shorter survival. Biopsies were then dissociated and sorted by flow cytometry into CD133-negative and CD133-positive cell populations. Both populations incorporated BrdU in cell culture, expressed neural precursor markers, and were equally tumorigenic when implanted into the brains of immuno-deficient rats. Moreover, the implanted CD133-negative cells gave rise to tumors that contained CD133-positive cells. CD133 expression was also characterized in 6 tumorgenic glioma cell lines. Even though all the cell lines were tumorigenic, immunocytochemistry, flowcytometry qRT-PCR and immunoblotting showed no expression of CD133 on the tumor cells. >In conclusion, the work demonstrates that also CD133-negative tumour cells can initiate brain tumour formation with similar take rates as their CD133-positive counterparts. Moreover, CD133 expression coincides with the onset of angiogenesis and a shorter survival suggesting a role for CD133-positive cells in tumour angiogenesis.